Sværere og livstruende hudreaktioner, herunder Stevens- Johnson syndrom, blev rapporteret hos mindre end 1 procent af patienterne i det kliniske udviklingsprogram.
Severe and life-threatening skin reactions, including Stevens-Johnson syndrome, were reported in less than 1% of patients included in the clinical development programme.